Company
Products
- Resminostat
- Partnered Products
Clinical Trials
- Ongoing / Planned
- Completed
Investors & Media
Careers

Startseite › Clinical Trials

Clinical Trials

Products

For more information about our epigenetic products please visit

Publications / Presentations / Posters

23. May 2025

Resminostat (Kinselby) received a Negative CHMP Opinion in the EU

20. May 2025

EMA signals a Negative CHMP Opinion on the Marketing Authorization Application for Resminostat (Kinselby)

28. Apr 2025

4SC announces further EMA feedback relating to Resminostat’s (Kinselby) Marketing Authorisation Application

Share this page:

Follow us on:

© 2025 - 4SC AG Seite drucken

Imprint
Privacy Policy
Contact